Company intelligence / Profile preview

Manchester BIOGEL

Alderley Edge, England, United Kingdom

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Manchester BIOGEL developed animal-free, chemically defined peptide hydrogels (PeptiGels, PeptiInks) that enable reproducible and scalable 3D cell culture, tissue engineering, organoid development, and facilitate collaborative research; the technology is recognized for potential clinical translation, but there are no direct therapeutics in clinical trials.

Therapeutic areas: Other
Modalities: Hydrogel-based drug delivery therapyDevice (bioprinting scaffold)
Industry: Non-Drug Biotech

Partnerships

Cellesce (3D organoid scaffolds partnership)[3]Qkine (Sustainable Innovation Fund collaboration)[5]Imperial College London (Knowledge Transfer Partnership for tumor models)[5]

Beyond the preview

Go deeper on Manchester BIOGEL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Manchester BIOGEL.

Explore the full profile